



February 12, 2014

To whom it may concern,

Company Name: Nichi-Iko Pharmaceutical Co., Ltd.

(Securities Code 4541 Tokyo Stock Exchange, First Section)

Representation: President/CEO Yuichi Tamura

Contact Information: President Office Mitsuru Azuma  
TEL 076-442-7026

### **Notice of Establishment of Subsidiary in USA**

Nichi-Iko established its 100% owned subsidiary named as NIXS Corporation in the State of Delaware, USA in January 14, 2014. In addition, Nichi-Iko's board meeting held in February 12, 2014 resolved to start full-fledged business in USA through NIXS Corporation.

#### 1. Purpose of Establishment of Subsidiary

Nichi-Iko group is now trying to expand its business to oversea territories based on the 6<sup>th</sup> middle range profit plan named as "Pyramid". And Nichi-Iko group has been getting ready for expanding to overseas business including NIXS Corporation as well as Nichi-Iko(Thailand) Co., Ltd. which was established in January, 2014. NIXS Corporation has a plan to develop and market biosimilar products and our in-line products including low molecular products and generic products in USA through collaboration with American partner.

This is the reason why Nichi-Iko established subsidiary in USA.

#### 2. Company Profile of Nichi-Iko's Subsidiary in USA

- (1) Company Name: NIXS Corporation
- (2) Address: 1209 Orange Street, City of Wilmington, County of New Castle, Delaware 19801
- (3) President: Taizan Kawakami
- (4) Main Business: Development and Marketing of Pharmaceutical Products

-----<END>-----